Kiadis Pharma NV has changed course and will in future focus its cell therapy capabilities on the development of natural killer (NK) cell products for the treatment of liquid and solid tumours. The Netherlands-based company acquired a portfolio of NK cell assets with the takeover of CytoSen Therapeutics Inc of the US in April.
